Castle Biosciences (CSTL) to Release Earnings on Thursday

Castle Biosciences (NASDAQ:CSTL) will issue its quarterly earnings data after the market closes on Thursday, May 2nd. Analysts expect the company to announce earnings of ($0.37) per share for the quarter. Castle Biosciences has set its FY 2024 guidance at EPS.Parties that wish to listen to the company’s conference call can do so using this link.

Castle Biosciences (NASDAQ:CSTL) last announced its quarterly earnings data on Wednesday, February 28th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.84) by $0.74. Castle Biosciences had a negative net margin of 26.15% and a negative return on equity of 14.92%. The firm had revenue of $66.12 million for the quarter, compared to analysts’ expectations of $51.32 million. On average, analysts expect Castle Biosciences to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Castle Biosciences Stock Performance

Shares of CSTL stock opened at $21.53 on Tuesday. Castle Biosciences has a 52-week low of $9.26 and a 52-week high of $26.70. The stock has a market cap of $591.00 million, a PE ratio of -9.97 and a beta of 0.93. The firm’s 50 day moving average price is $21.01 and its two-hundred day moving average price is $20.16.

Analyst Ratings Changes

CSTL has been the topic of a number of recent research reports. Scotiabank raised their price objective on shares of Castle Biosciences from $33.00 to $37.00 and gave the company a “sector outperform” rating in a research note on Friday, March 1st. KeyCorp increased their target price on shares of Castle Biosciences from $25.00 to $28.00 and gave the stock an “overweight” rating in a report on Friday, March 1st.

Insiders Place Their Bets

In other Castle Biosciences news, insider Derek J. Maetzold sold 1,947 shares of the stock in a transaction on Friday, April 12th. The shares were sold at an average price of $20.35, for a total value of $39,621.45. Following the sale, the insider now directly owns 65,418 shares in the company, valued at $1,331,256.30. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, Director Daniel Bradbury sold 2,074 shares of Castle Biosciences stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $23.20, for a total transaction of $48,116.80. Following the completion of the sale, the director now owns 33,870 shares of the company’s stock, valued at approximately $785,784. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Derek J. Maetzold sold 1,947 shares of Castle Biosciences stock in a transaction dated Friday, April 12th. The stock was sold at an average price of $20.35, for a total transaction of $39,621.45. Following the sale, the insider now directly owns 65,418 shares of the company’s stock, valued at approximately $1,331,256.30. The disclosure for this sale can be found here. Over the last three months, insiders have sold 50,483 shares of company stock worth $1,059,531. Company insiders own 7.20% of the company’s stock.

Castle Biosciences Company Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.